Status:
COMPLETED
Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 1
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
This trial is conducted in Europe, Oceania and the United States of America (USA). The aim of this trial is to compare two NN1250 (insulin degludec) formulations with each other and with insulin glarg...
Eligibility Criteria
Inclusion
- Type 1 diabetes for at least one year
- HbA1c 7-11% (both inclusive)
- Treated with insulin for at least six months - any regimen
Exclusion
- Any systemic treatment with products which in the Investigator's opinion could interfere with glucose or lipid metabolism (eg systemic corticosteroids) 3 months prior to randomisation
- Subject has a clinically significant, active (during the past 12 months) disease of the gastrointestinal, pulmonary, neurological, genitourinary, or haematological system that, in the opinion of the Investigator, may confound the results of the trial or pose additional risk in administering trial product
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2008
Estimated Enrollment :
178 Patients enrolled
Trial Details
Trial ID
NCT00612040
Start Date
January 1 2008
End Date
June 1 2008
Last Update
March 3 2017
Active Locations (33)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Walnut Creek, California, United States, 94598
2
Novo Nordisk Investigational Site
Honolulu, Hawaii, United States, 96814
3
Novo Nordisk Investigational Site
Idaho Falls, Idaho, United States, 83404-7596
4
Novo Nordisk Investigational Site
Des Moines, Iowa, United States, 50314